Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2025 11:00 ET | Source: Rapafusyn Pharmaceuticals

Rapafusyn Pharmaceuticals to Showcase Its Molecular Glue Drug Discovery Platform at WuXi Global Forum

BALTIMORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a pioneer in non-degrading molecular glue therapeutics, announced today that it will host an executive roundtable at the WuXi...
October 23, 2024 11:06 ET | Source: Rapafusyn Pharmaceuticals

Rapafusyn Announces an Upcoming Oral Presentation at Targeted Protein Degradation & Induced Proximity Summit

BALTIMORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce an upcoming oral presentation at the 7th Targeted Protein Degradation & Induced Proximity Summit...
October 17, 2024 10:24 ET | Source: Rapafusyn Pharmaceuticals

Rapafusyn Pharmaceuticals to Present In Vivo Data on ENT1 Inhibitor for Acute Kidney Injury at the American Society for Nephrology (ASN Kidney Week 2024)

BALTIMORE, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a leader in the field of non-degrading molecular glues, is pleased to announce the upcoming presentation of preclinical in...
June 20, 2024 10:46 ET | Source: Rapafusyn Pharmaceuticals

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets Financing...
April 01, 2024 16:08 ET | Source: Rapafusyn Pharmaceuticals

Rapafusyn Announces Multiple Presentations at the 2024 Drug Discovery Chemistry Conference

BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce two upcoming presentations at Cambridge Health Institute’s 12th Annual Oral Peptides & Macrocyclics...